We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out).

I'm ok with this

Corporate publications | Resources | Media | Grünenthal Group

Corporate Publications

11 April 2018 / Our Stories

Giving CRPS patients hope

Neridronate is giving hope to those affected by CRPS – one of the most painful conditions a patient can experience.

Neridronate is giving hope to those affected by CRPS – one of the most painful conditions a patient can experience.

Complex Regional Pain Syndrome (CRPS) is a rare condition that typically affects patients following a soft tissue, bone, or nerve injury. Patients with CRPS have to live with very severe and persistent pain – and no sufficiently effective treatments are available. For this reason, people with CRPS report lower quality of life scores than patients with most other chronic pain conditions. Patients frequently become socially isolated, lose their employment, and/or suffer from depression.

“We are committed to putting patients’ needs first and will push further to make neridronate the first approved medication for CRPS in the US.”

Dr. Klaus-Dieter Langner,

Chief Scientific Officer Grünenthal

 

Our experts are striving to provide hope for patients with CRPS. The bisphosphonate, neridronate, is an innovative new medicine originally discovered and developed by Abiogen Pharma and now being further developed by Grünenthal for the US market. The U.S. Food and Drug Administration (FDA) recognized the unmet need in CRPS and the potential of neridronate in this disease by granting Breakthrough Therapy and Fast Track designation. We will continue the clinical development of neridronate to give people with CRPS the quality of life they deserve.

Share this Story: